Advertisement
UK markets open in 1 hour 49 minutes

  • NIKKEI 225

    38,350.59
    -882.21 (-2.25%)
     

  • HANG SENG

    16,279.56
    -320.90 (-1.93%)
     

  • CRUDE OIL

    85.94
    +0.53 (+0.62%)
     

  • GOLD FUTURES

    2,403.30
    +20.30 (+0.85%)
     

  • DOW

    37,735.11
    -248.13 (-0.65%)
     

  • Bitcoin GBP

    50,312.33
    -2,000.78 (-3.82%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • NASDAQ Composite

    15,885.02
    -290.08 (-1.79%)
     

  • UK FTSE All Share

    4,338.90
    -14.76 (-0.34%)
     
Stocks:

Trending tickers: Oil, Goldman Sachs, Bitcoin and Ethereum

The latest investor updates on stocks that are trending on Monday

Exelixis (EXEL) Looks Good: Stock Adds 17.2% in Session

Zacks Equity Research
Updated

Exelixis, Inc. EXEL was a big mover last session, as the company saw its shares rise more than 17% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $23.35 to $28.27 in the past one-month time frame.

The move came after the company announced that its global phase 3 CELESTIAL trial met the primary endpoint to heal liver cancer patients with Cabometyx, which will provide significant improvement in comparison to placebo. Also, the company obtained the U.S. Food and Drug Administration approval for supplemental New Drug Application (sNDA) for the treatment of advanced renal cell carcinoma.

The company has seen one positive estimate revision in the past one month, while its Zacks Consensus Estimate for the current quarter has remained unchanged. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Exelixis currently has a Zacks Rank #3 (Hold), while its Earnings ESP is negative.

Exelixis, Inc. Price

Exelixis, Inc. Price | Exelixis, Inc. Quote

ADVERTISEMENT

A better-ranked stock in the Medical - Biomedical and Genetics industry is Axovant Sciences Ltd. AXON, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is EXEL going up? Or down? Predict to see what others think: Up or Down

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Exelixis, Inc. (EXEL) : Free Stock Analysis Report
 
Axovant Sciences Ltd. (AXON) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research